Business Context and Reporting Period
This Form 8-K Current Report was filed by Henry Schein, Inc. on May 19, 2009. The report addresses a specific corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure of personnel changes and contains no financial data.
Material Changes
The material change disclosed is the voluntary resignation of Dr. Margaret A. Hamburg from her position as a member of the Board of Directors. Additionally, she withdrew her name as a nominee for re-election at the Company's forthcoming Annual Meeting of Stockholders scheduled for May 28, 2009.
Outlook, Commentary, and Risks
- Reason for Departure: Dr. Hamburg was confirmed as the Commissioner of the U.S. Food and Drug Administration (FDA). Her responsibilities in this new role preclude her continued service on the Board.
- Nature of Departure: The resignation was not the result of any disagreement with the Company.
- Replacement Plans: The Company has no current intention of naming another director to replace Dr. Hamburg as a current director or as a nominee for the upcoming election.
Key Facts for Investor Verification
- Dr. Margaret A. Hamburg resigned from the Board of Directors effective May 19, 2009.
- The resignation is due to her confirmation as FDA Commissioner.
- Henry Schein, Inc. does not intend to fill the vacancy immediately for the upcoming May 28, 2009 Annual Meeting.
- No financial performance data is included in this specific filing.